Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesObstetrics/GynecologyAetna Endometrial Cancer Coverage Update | OpenPay…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentAetnaPolicy 0769

    Endometrial Cancer Screening, Diagnosis, and Prognosis

    Customize your policy alerts

    Sign up for Aetna Policy 0769 alerts

    Get alerted when Policy 0769 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Clinical policy governing medically necessary and investigational tests and procedures for screening, diagnosis, and prognosis of endometrial cancer, applicable to Aetna-covered persons and providers submitting claims under this policy.

    Policy Summary
    PayerAetna
    PolicyEndometrial Cancer Screening, Diagnosis, and Prognosis
    Policy CodePolicy 0769
    Change TypeNo material change
    Effective DateNov 7, 2008
    Last ReviewOct 26, 2023
    Next Review DateAug 22, 2024
    Key ActionDocument diagnostic indication when requesting coverage for endometrial sampling (e.g., abnormal uterine bleeding or Lynch syndrome surveillance).
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    94%SLN mapping sensitivity (pooled)
    99.6% NPVSLN mapping NPV (FIRES)
    5,348SLN meta-analysis patients
    95% sensitivityTao Brush sensitivity
    Many testsBiomarkers listed as investigational

    Coverage Criteria — Medically Necessary and Investigational

    Medically necessary

    Aetna considers the following medically necessary:

    Medically necessary endometrial sampling and procedures: Endometrial biopsy (sampling) for histologic tissue examination in the diagnostic evaluation of abnormal uterine bleeding in women suspected of having endometrial hyperplasia or endometrial carcinoma; and for endometrial cancer surveillance in women with Lynch syndrome.

    Supports CPT 58100, 58110, 58558 when selection criteria are met.

    Acceptable alternative: Endometrial brush (Tao Brush) is an acceptable alternative to an endometrial suction curette (e.g., Pipelle) for medically necessary endometrial sampling.
    Surgical staging: Sentinel lymph node mapping for pathologic evaluation and surgical staging in persons with endometrial cancer is considered medically necessary.

    Supports CPT 38792, 38900, 78195 and related codes when clinically indicated.

    Policy Summary
    PayerAetna
    PolicyEndometrial Cancer Screening, Diagnosis, and Prognosis
    Policy CodePolicy 0769
    Change TypeNo material change
    Effective DateNov 7, 2008
    Last ReviewOct 26, 2023
    Next Review DateAug 22, 2024
    Key ActionDocument diagnostic indication when requesting coverage for endometrial sampling (e.g., abnormal uterine bleeding or Lynch syndrome surveillance).
    SourceLink
    On This Page
    Coverage Criteria — Medically Necessary and InvestigationalCoding — CPT/HCPCS/ICD and Related NotesProvider Actions, Prior Authorization, and DocumentationBackground and ScopeDefinitions and Device/Term Descriptions

    Experimental / Investigational (Not covered)

    Aetna considers the following experimental and investigational because effectiveness has not been established:

    Listed investigational tests: Circulating adiponectin, leptin, adiponectin-leptin ratio; circulating and endometrial tissue microRNA markers; circular RNAs expression; DNA methylation; endometrial biopsy for screening; endometrial or cervical cytology performed in conjunction with endometrial histology (TruTest/Gynecor); FTO rs9939609 and HSD17B1 rs605059 gene polymorphism testing; PTEN immunohistochemistry for differential diagnosis; measurement of blood anti-Müllerian hormone (AMH); circulating YKL-40; serum HE4; urine microRNAs; L1CAM expression; NGAL; telomeres/telomerase activity; metabolomics; single nucleotide polymorphism testing; UBE2C, WNT5a, ZEB1 for prognosis — all considered experimental/investigational and not established as effective for screening, diagnosis, or prognosis.

    These items are listed as experimental/investigational and not established as effective for screening, diagnosis, or prognosis.

    When further evaluation is indicated after endometrial sampling

    Covered when ANY of the following clinical indications are present:

    Indications for further evaluation: Persistent abnormal uterine bleeding despite a negative outpatient endometrial biopsy; a thick endometrial stripe, persistent bleeding, or bleeding in a post- or peri-menopausal woman; any postmenopausal bleeding (even minimal) in a woman not on hormone therapy.

    In asymptomatic postmenopausal women with endometrial stripe <5 mm and no risk factors, biopsy is not indicated; persistent symptoms despite negative biopsy warrant additional evaluation (eg, hysteroscopy with curettage).

    Surveillance in Lynch syndrome

    Covered when ALL of the following are met:

    Lynch surveillance: Patient has Lynch syndrome (personal or family history or tumor testing consistent with mismatch repair gene mutation); and annual endometrial sampling and transvaginal ultrasound beginning at age 30–35 years.

    Document family/personal history and tumor testing used to evaluate for Lynch syndrome when requesting surveillance.

    Evidence summaries and coverage-relevant conclusions

    Summary of evidence-based findings and conclusions reported in the document:

    microRNA findings: microRNA signatures (eg, SMAD4 inhibition/TGF-β pathway impairment) show potential diagnostic value for distinguishing endometrial hyperplasia with atypia and improving understanding of carcinogenesis, but are preliminary and not clinically validated.

    See systematic and discovery studies; further validation required.

    Adiponectin/leptin evidence: Meta-analyses report inverse association of circulating adiponectin and adiponectin:leptin ratio, and higher leptin associated with increased endometrial cancer risk in observational studies; prospective validation is needed.

    Findings stronger in postmenopausal women and in some subgroups.

    Gene polymorphisms: FTO rs9939609 polymorphism has been associated with endometrial cancer risk in some analyses and ethnic subgroups; HSD17B1 rs605059 showed no significant association—results heterogeneous and require further study.
    NGAL as biomarker: NGAL expression associated with worse overall survival in endometrial cancer (pooled HR ~4.38) in meta-analyses, but clinical application remains uncertain.
    Telomerase/telomere research: Telomerase activity and telomere length show biologic associations with endometrial proliferation; in-vitro telomerase inhibition altered epithelial proliferation, but clinical relevance is unproven.

    Existing data are mechanistic and require in-vivo confirmation.

    Sentinel lymph node mapping (SLN): SLN mapping with cervical ICG injection demonstrates high detection rates and diagnostic accuracy (sensitivity ~94–97%, NPV ~99–100%) and may be considered an alternative to full lymphadenectomy for staging; it may miss metastases in a small proportion (~3%) of node-positive patients.

    ICG and cervical injection techniques improved overall and bilateral detection versus other tracers; studies include FIRES and multiple meta-analyses.

    Evidence summaries (diagnosis/prognosis)

    Summaries of evidence-based findings and authors' conclusions

    Sentinel lymph node (SLN) mapping evidence: SLN mapping with ICG demonstrated higher overall and bilateral detection rates and pooled diagnostic accuracy (sensitivity ~94%, NPV ~100%); SLN mapping may safely replace full lymphadenectomy for staging in many patients though it will not identify metastases in a small percentage (~3%) of node-positive patients.

    ICG had the highest detection rates compared with blue dye and technetium-99; SLN mapping associated with similar survival/recurrence outcomes and increased likelihood of receiving adjuvant therapy.

    Molecular and biomarker assays under investigation: DNA methylation markers show high pooled sensitivity (~0.93) but low specificity (~0.48); circRNA, metabolomics, PTEN IHC (AUC ~0.657), L1CAM overexpression (HRs indicating worse OS/DFS), and other molecular markers have preliminary signals but are limited by small, heterogeneous, and retrospective studies requiring validation.

    Most biomarker findings are preliminary and not ready for routine clinical use.

    Measurement of endometrial thickness by transvaginal ultrasonography (TVUS) for the purpose of screening asymptomatic postmenopausal women who are not receiving hormone replacement therapy is not supported as an effective screening strategy. Systematic reviews pooling data from multiple studies (32 studies, 11,100 women) found a low prevalence of (pre-)malignancy (pooled prevalence ~0.62%) and summary diagnostic estimates that do not justify routine screening: for a 5 mm cut-off pooled sensitivity and specificity were variable (summary sensitivity ~0.83, specificity ~0.72), while other thresholds showed trade-offs between sensitivity and specificity. Consequently, routine endometrial-thickness measurement in asymptomatic postmenopausal women without HRT is not recommended as a screening test for endometrial carcinoma or atypical hyperplasia.

    Transvaginal ultrasound measurement of endometrial thickness is not justified as a screening test for endometrial carcinoma or atypical endometrial hyperplasia in asymptomatic postmenopausal women not using hormone replacement therapy. The pooled evidence demonstrates limited predictive value across evaluated cut-offs and a low population prevalence of disease, and claims billed as screening (ICD-10 Z12.79) are listed as not covered for the indications addressed in this policy.

    Sentinel lymph node (SLN) biopsy/mapping for endometrial carcinoma remains an area of active investigation. Earlier systematic reviews and meta-analyses report variable detection rates and sensitivities (e.g., pooled detection ~78% and sensitivity ~93% in some series), and expert reviews (UpToDate) and guideline statements historically considered SLN biopsy investigational for endometrial cancer. Although more recent studies (summarized elsewhere in this policy) support SLN mapping with cervical indocyanine green (ICG) injection as a technique with high detection and diagnostic accuracy, the literature also documents heterogeneity between studies and the need for further investigation to establish standard clinical utility and optimal procedural technique.

    Data on telomerase inhibition derive from short-term in-vitro, mono-cellular experiments showing that telomerase inhibition (for example, with imetelstat) can reduce epithelial cell telomerase activity and proliferation and disrupt glandular architecture in culture. These mechanistic and preclinical findings cannot be extrapolated to support clinical treatment without confirmatory in-vivo studies and additional translational evidence.

    The National Comprehensive Cancer Network (NCCN) guidance cited in the policy does not include DNA methylation testing, single nucleotide polymorphism testing, or anti-Müllerian hormone measurement as recommended routine tools for screening or diagnosis of endometrial cancer. Systematic reviews of DNA methylation studies report high pooled sensitivity but relatively low specificity and emphasize the need for standardized targets and methods before clinical adoption.

    The studies evaluated for emerging biomarkers and molecular assays are limited by small sample sizes, homogeneous (mostly Caucasian) study populations, retrospective designs, and heterogeneous methodologies (including differences in sample type, assay methods, and lack of standardized expression cut-offs). These limitations reduce generalizability and preclude definitive conclusions about clinical performance and utility.

    Use of the listed biomarker and molecular tests (including but not limited to circulating YKL-40, HE4, urine microRNAs, DNA methylation panels, circulating and tissue microRNA markers, circular RNAs, telomere/telomerase measures, metabolomics, SNP and polymorphism testing, AMH, NGAL, L1CAM, UBE2C, WNT5a, and ZEB1) for screening, diagnosis, or prognosis of endometrial cancer is considered experimental / investigational and not medically necessary because effectiveness and clinical validity have not been established.

    Routine transvaginal ultrasonography (TVUS) measurement of endometrial thickness as a screening tool in asymptomatic postmenopausal women (not on hormone replacement therapy) is not supported by the evidence. Systematic reviews and meta-analyses demonstrate low prevalence of occult malignancy and variable diagnostic performance at commonly evaluated thresholds (for example, the 5 mm threshold does not reliably exclude disease in all series), and therefore TVUS-based endometrial thickness screening is not recommended.

    Biomarkers and genetic polymorphisms (including various microRNAs, FTO rs9939609, and other polymorphisms) demonstrate biological associations with endometrial carcinogenesis or risk in exploratory and retrospective studies, and some show mechanistic plausibility. However, these findings are preliminary, heterogeneous across studies, and lack the prospective validation and standardized assays necessary for routine clinical implementation.

    Immunohistochemistry for PTEN (protein phosphatase and tensin homolog) has demonstrated low diagnostic accuracy in meta-analyses comparing benign versus pre-malignant endometrial hyperplasia (pooled AUC ~0.657 and sensitivity/specificity estimates that are limited). Authors of systematic reviews note variability in definitions of PTEN loss and recommend reevaluation of routine PTEN IHC use pending further evidence.

    MicroRNA markers are not currently feasible for routine diagnostic use. The literature lacks fully characterized, standardized extraction and assay methods, and there are no well-established expression cut-off points linked to clinical decision thresholds; many studies are retrospective, small, and heterogeneous, limiting their immediate clinical applicability.

    Coding — CPT/HCPCS/ICD and Related Notes

    Covered CPT/HCPCS/ICD-10 and related codes / Not covered screening codemixed
    38792Injection procedure; radioactive tracer for identification of sentinel node.
    38900Intraoperative identification (eg, mapping) of sentinel lymph node(s) includes injection of non-radioactive dye.
    58100Endometrial sampling (biopsy) with or without endocervical sampling, without cervical dilation, any method.
    58110Endometrial sampling (biopsy) performed in conjunction with colposcopy.
    58558Hysteroscopy, surgical; with sampling (biopsy) of endometrium and/or polypectomy, with or without D & C.
    78195Lymphatics and lymph nodes imaging [sentinel lymph node biopsy].
    81321PTEN gene analysis; full sequence analysis.
    81322PTEN gene analysis; known familial variant.
    81323PTEN gene analysis; duplication/deletion variant.
    86305Human epididymis protein 4 (HE4).
    1–10 of 25
    1/3
    Covered CPT Codesmixed
    No codes listed
    Pipelle detection rates — key performance metrics
    Pipelle detection rate — postmenopausal99.6% detection rate for endometrial carcinoma (meta-analysis).
    Pipelle detection rate — premenopausal91% detection rate for endometrial carcinoma (meta-analysis).
    Pipelle sensitivity for atypical hyperplasia81% sensitivity for detection of atypical hyperplasia (single study reported).
    Endometrial thickness cut-offs (TVUS) — reported thresholds
    5 mm cut-off (TVUS)Commonly evaluated to rule out need for biopsy in asymptomatic postmenopausal women; pooled sensitivity ~0.83 and specificity ~0.72 for predicting endometrial carcinoma (5-mm cut-off).
    6 mm cut-off (TVUS)Reported pooled sensitivity ~0.33 and specificity ~0.94 for predicting endometrial carcinoma (from systematic review).
    11.5 mm cut-off (TVUS)In post-menopausal women with endometrial polyps, 11.5 mm cut-off showed sensitivity 53.8% and specificity 85.8% for pre-malignant/malignant polyps (Cavkaytar et al.).
    13 mm cut-off (TVUS)In hysteroscopic polyp series, 13 mm endometrial thickness showed sensitivity 69.6% and specificity 68.5% for malignant polyps (Godoy et al.).
    19.5 mm polyp size (hysteroscopy)Polyp size ≥19.5 mm on hysteroscopy associated with higher diagnostic accuracy (sensitivity 92.3%, specificity 95.0% for malignant polyps in one study).

    Provider Actions, Prior Authorization, and Documentation

    Prior Authorization

    Prior authorization / coverage note — document indication and selection criteria

    Certain CPT/HCPCS codes (for example, 38792, 38900, 58100, 58110, 58558, 78195 and selected molecular/pathology codes) are listed in the policy as covered when the policy’s selection/clinical criteria are met; when requesting coverage or authorization, document the diagnostic indication and which selection criteria apply.

    • Support prior authorization requests with documentation of the clinical indication (e.g., abnormal uterine bleeding, surveillance for Lynch syndrome) and the specific selection criteria met.
    • If submitting codes for SLN mapping or sentinel-node imaging (e.g., 38792, 38900, 78195), reference the clinical staging indication and intraoperative mapping technique used.
    Prior Authorization

    SLN mapping — prior authorization considerations and documentation

    SLN biopsy/mapping for endometrial carcinoma is discussed as investigational/ needing further study in background reviews; when used, the policy notes SLN mapping should be supported by documentation of investigational status or trial enrollment where applicable.

    • If using SLN mapping in a setting considered investigational at the time, document rationale (clinical trial enrollment or supporting evidence) when requesting authorization.
    • Include details of injection technique (e.g., cervical ICG) and planned staging approach to support clinical justification.
    Prior Authorization

    Prior authorization — evidence summary does not specify payer mandates

    The policy does not list payer-specific prior-authorization codes or mandates; it summarizes evidence supporting SLN mapping (standardized cervical ICG injection and high diagnostic accuracy) but does not convert that evidence into explicit authorization requirements.

    • When seeking authorization for SLN mapping, include study-relevant technique details (ICG cervical injection, planned ultrastaging) and clinical staging indication since no payer-specific codes/mands are provided in the bulletin.
    • Provide documentation of mapping method and expected pathology processing to align with evidence cited (e.g., hematoxylin & eosin with ultrastaging and cytokeratin IHC for negative SLNs).
    Prior Authorization

    No specific prior authorization requirements stated in this policy excerpt

    The bulletin excerpts do not state specific prior authorization requirements for SLN mapping or for the molecular/biomarker tests described; do not assume automatic prior‑authorization rules from this policy text alone.

    • If an individual payer (not documented in this policy excerpt) requires prior authorization, follow that payer’s administrative process and provide clinical documentation as noted in the policy.
    • For investigational biomarker testing, include protocol/consent or research documentation if applicable.
    Prior Authorization

    No prior authorization specified for biomarker testing in these excerpts

    The extracted sections do not describe any specific prior‑authorization requirements for biomarker testing; when ordering investigational biomarker or molecular assays, document study details and clinical rationale to support testing.

    • Include study/sample details (assay type, sample size, marker panel) and a clinical interpretation plan in the record when investigational biomarkers are performed.
    • Confirm and follow any separate payer-specific prior authorization processes that may apply to genetic/molecular testing.
    Note

    Prior authorization note — bulletin is informational; verify payer rules

    This Clinical Policy Bulletin is informational about benefits administration and does not state specific prior authorization mandates in the extracted portions; verify payer-specific authorization rules before submission.

    • Treat the bulletin as guidance for clinical coverage stance; contact the member’s plan for any required prior authorization steps or forms.
    • Document the clinical indication and selection criteria in the chart to support any authorization request.
    Note

    No action specified

    (No additional provider action specified in this excerpt.)

    Step Therapy

    No step‑therapy required for SLN mapping — treat as alternative staging strategy

    No step therapy or sequential treatment requirements are described for SLN mapping; the policy discusses SLN mapping as an alternative staging strategy (often using ICG cervical injection) rather than a step in a therapy sequence.

    • Do not interpret the policy as imposing step‑therapy; document the clinical staging indication and mapping technique when requesting authorization or submitting claims.
    • If using SLN mapping instead of full lymphadenectomy, document rationale and planned intraoperative/pathology procedures.
    Step Therapy

    No step‑therapy requirements for diagnostic/prognostic tests in excerpt

    No step therapy requirements are described for diagnostic or prognostic modalities in this policy excerpt; ordering clinicians should document clinical indications and any investigational status when applicable.

    • For molecular or experimental diagnostics, include research/protocol details and clinical rationale in the medical record to support medical necessity or investigational use.
    • Follow payer-specific administrative rules for prior authorization or coverage determinations.
    Step Therapy

    No step‑therapy for biomarker/molecular testing — document study details and limitations

    No step therapy requirements are described for biomarker or molecular testing in the provided section; when ordering such tests, document study details, assay type, and clinical rationale in the record.

    • Document sample size, assay platform, and identified markers when performing investigational biomarker testing.
    • Provide justification for clinical use versus research and note limitations cited in the policy (small cohorts, heterogeneous methods).
    Note
    Documentation Required

    Document diagnostic indication when billing endometrial sampling

    Endometrial sampling codes (for example, CPT 58100, 58110, 58558) are covered when selection criteria are met; providers must document the diagnostic indication (e.g., abnormal uterine bleeding) to support medical necessity.

    • When billing endometrial sampling, include clinical indication in the chart (abnormal uterine bleeding, surveillance for Lynch syndrome, postmenopausal bleeding, etc.).
    • If billing for screening (ICD-10 Z12.79), note that this encounter code is listed as not covered in the policy and may be denied.
    Documentation Required

    Document Lynch‑syndrome surveillance (annual sampling and TVUS starting 30–35 yrs)

    For women with Lynch syndrome, document annual endometrial sampling and transvaginal ultrasound beginning at age 30–35, and include family/personal history or tumor testing consistent with Lynch syndrome to support surveillance coding and medical necessity.

    • Document family and personal history and any tumor testing used to evaluate for Lynch syndrome.
    • Record that surveillance is being performed annually beginning at age 30–35 as indicated by guidelines cited in the policy.
    Documentation Required

    Document SLN mapping technique and pathology processing (ICG, ultrastaging, IHC)

    When performing SLN mapping, document intraoperative technique (standardized cervical injection of indocyanine green when used), mapping results, and pathology processing (H&E staining with ultrastaging and cytokeratin IHC on negative SLNs) in the operative and pathology reports.

    • Record injection tracer and site (e.g., ICG — cervical injection), number and laterality of mapped SLNs, and any completion lymphadenectomy performed.
    • Include pathology protocol: H&E staining, ultrastaging, and immunohistochemistry for cytokeratin on negative SLNs as described in the FIRES study.
    Documentation Required

    No explicit procedural authorization requirements stated — document clinical/test details

    The extracted excerpts do not state explicit documentation or procedural authorization requirements beyond the clinical and technique details referenced in the evidence summaries; focus documentation on clinical indication, technique, and study/test details when applicable.

    • For investigational biomarker tests, document study/sample details, assay type, and limitations to support interpretation and any investigational claims.
    • Ensure operative and pathology reports fully describe mapping technique and specimen handling to align with evidence summaries.
    Documentation Required

    Document study details for investigational biomarker testing (sample size, assay, markers, limitations)

    When investigational biomarker testing is performed, document study details in the clinical record: sample sizes, assay type/platform, identified markers, and study limitations to support interpretation and potential research use.

    • Record the assay platform (for example, HPLC-TQ/MS for targeted metabolomics), the markers tested (e.g., ceramides, acylcarnitines), and the reference study cohort size.
    • Note limitations cited in the policy (small cohorts, heterogeneous methods) in the clinical record to contextualize test results.
    Note

    Providers are responsible for medical decisions; bulletin is informational

    Treating providers are solely responsible for medical advice and treatment; the Clinical Policy Bulletin is informational and does not replace clinical judgment or constitute a contract or offer of coverage.

    • Make treatment decisions based on the patient’s clinical needs and current standards of care; use the bulletin to guide coverage discussions but confirm benefits with the payer.
    • Keep complete documentation to support medical necessity and any coverage determinations.
    Denial Risk

    Exclude screening code Z12.79 — billing as screening may be denied

    Do not bill screening encounter code Z12.79 for endometrial cancer when the service is being provided as diagnostic or surveillance for symptoms/risk; the policy lists Z12.79 as not covered and claims billed as screening may be denied.

    • If the patient has symptoms (e.g., any postmenopausal bleeding) or surveillance indications (e.g., Lynch syndrome), use the appropriate diagnostic or surveillance ICD-10 code rather than Z12.79.
    • Review payor coverage guidance before submitting claims that might be interpreted as screening.
    Denial Risk

    Escalate evaluation for persistent symptoms; biopsy indicated for any postmenopausal bleeding

    If symptoms persist despite a negative outpatient endometrial biopsy, pursue further evaluation; in asymptomatic postmenopausal women an endometrial stripe <5 mm generally does not require biopsy, but any postmenopausal bleeding—even one drop—constitutes an indication for biopsy.

    • Document persistence of symptoms when pursuing additional sampling or hysteroscopy with curettage.
    • Record endometrial stripe measurement and rationale when deciding whether to proceed to biopsy in asymptomatic patients.
    Prior Authorization

    SLN mapping evidence present but no explicit prior‑authorization mandates in text

    The policy provides evidence on SLN mapping accuracy and feasibility but does not specify provider prior‑authorization or documentation mandates for SLN mapping; follow local payer processes and document clinical justification and mapping technique.

    • Provide technique and pathology details (ICG cervical injection, ultrastaging) when requesting authorization or submitting claims for SLN mapping.
    • If the payer requires prior authorization, supply the evidence-based justification described in the policy (detection and diagnostic accuracy data).
    Denial Risk

    No explicit denial triggers listed — missing documentation or non‑covered codes may cause denials

    The excerpts do not identify explicit denial triggers for the procedures/tests discussed; however, lack of required documentation or use of codes listed as not covered (e.g., screening code Z12.79) may lead to denials.

    • Ensure documentation of medical necessity and selection criteria when billing to avoid administrative denials.
    • Avoid billing investigational biomarker tests with standard coverage codes unless payer guidance permits and documentation is provided.
    Prior Authorization

    Investigational biomarkers — no explicit coverage requirements stated; document details

    The policy excerpts do not state specific authorization or coverage requirements for investigational biomarkers; treat these assays as investigational and provide full documentation of study/testing details and clinical rationale when ordered.

    • Include assay method, markers tested, and study limitations in the medical record for investigational biomarkers.
    • Confirm any separate payer preauthorization requirements for molecular or genetic tests prior to ordering.
    Note

    Definitions and Device/Term Descriptions

    Tao Brush (endometrial brush) — definition and evidence
    Device class and purposeTao Brush is an FDA Class II cytologic/endometrial sampling device used to obtain endometrial cells for cytology and histology.
    Comparative performanceSome studies report high sensitivity (e.g., 95.5% sensitivity in Del Priore et al.) and high specificity when compared with Pipelle in small comparative trials.
    Clinical roleEvaluated as an alternative to Pipelle and other blind sampling methods; evidence limited to small studies and case series.
    Pipelle — device description and performance
    DefinitionPipelle is a suction endometrial sampling device commonly used for endometrial biopsy (most popular method).
    Detection performanceMeta-analysis found Pipelle detection rates for endometrial carcinoma of 99.6% in postmenopausal and 91% in premenopausal women, and high specificity (>98%).
    Clinical useUsed as a minimally invasive alternative to D&C or hysteroscopy for histologic evaluation in abnormal uterine bleeding and surveillance contexts.
    Lynch syndrome (HNPCC) — definition and surveillance
    Genetic basisLynch syndrome (HNPCC) is an autosomal-dominant inherited cancer susceptibility caused by germline mismatch repair gene mutation.
    Cancer riskAssociated with early onset and multiple cancers; lifetime cumulative risk of endometrial cancer in women with Lynch syndrome is approximately 40–60%.
    Surveillance recommendationCurrent guidelines include annual endometrial sampling and transvaginal ultrasound beginning at age 30–35 years for women with Lynch syndrome.
    Sentinel lymph node (SLN) biopsy/mapping — summary of evidence
    Technique overviewSentinel lymph node (SLN) biopsy/mapping identifies first-draining lymph nodes for evaluation of metastatic spread and can reduce morbidity compared with full lymphadenectomy.
    Detection and bilateral ratesPooled overall detection ~87%, bilateral detection ~61%; use of ICG increases overall detection to ~94% and bilateral detection to ~74%.
    Diagnostic accuracyPooled sensitivity ~94% and NPV ~100% (meta-analysis); FIRES study reported sensitivity 97.2% and NPV 99.6%.
    Technique variations and injection siteInjection site affects detection; peri-cervical (cervical) injection and ICG tracer associated with higher detection rates; hysteroscopic or subserosal techniques may reduce detection/sensitivity.
    microRNA signature (SMAD4 inhibition) — summary
    Biological mechanismmicroRNA signature implicates SMAD4 inhibition leading to impairment of the TGF-β pathway in endometrial carcinoma development.
    Diagnostic potentialFindings suggest a potential diagnostic role for distinguishing endometrial hyperplasia with atypia / endometrial intraepithelial neoplasia, but clinical utility is not established.
    Evidence limitationsStudies are preliminary and heterogeneous; further validation needed before routine clinical use.
    NGAL — definition and evidence
    Analyte and sample typesNGAL (neutrophil gelatinase-associated lipocalin) levels measured in plasma or urine have been evaluated as prognostic and diagnostic markers in cancer, including endometrial cancer.
    Prognostic signalMeta-analysis reported NGAL as a negative prognostic marker for overall survival in endometrial cancer (HR = 4.38).
    Diagnostic performanceDiscriminative power varies by tumor type; pooled AUC and sensitivity/specificity differ across cancers and are moderate to good in some settings.
    Sentinel lymph node (SLN) mapping — intraoperative technique
    Definition and methodSLN mapping is an intraoperative technique to identify first draining lymph nodes, often via cervical injection of tracer (commonly ICG) for targeted biopsy.
    Evidence baseSystematic reviews and the FIRES prospective study demonstrate high detection rates and diagnostic accuracy; pooled sensitivity ~94–97% and NPV ~99–100%.
    Clinical implicationSLN mapping may be considered an alternative to full lymphadenectomy for staging in endometrial cancer, though some authorities previously considered it investigational and technique-dependent.
    microRNA (miR) — definition and research status
    DefinitionmicroRNAs (miRs) are single-stranded non-coding RNA molecules (19–25 nucleotides) that regulate post-transcriptional gene expression.
    Research findingsLiterature surveys have identified many (e.g., 138) miRs with potential diagnostic, prognostic, or treatment-response relevance in endometrial cancer, but studies are heterogeneous.
    Clinical readinessmiR markers are exploratory; methodological heterogeneity and lack of standardized cut-offs limit current clinical use.
    Metabolomics (targeted) — definition and evidence
    MethodTargeted metabolomics uses platforms such as HPLC-TQ/MS to profile endogenous metabolites (e.g., ceramides, acylcarnitines) in serum or plasma for diagnostic biomarker discovery.
    Preliminary performanceIn a small targeted study (n=15 EC, n=21 controls), a 4-biomarker panel (ceramides, acylcarnitines, 1-methyladenosine) achieved 94% sensitivity and 75% specificity (AUC 92.5%).
    LimitationsCohorts are small and findings require validation in larger, diverse populations before clinical application.